In a 2019 study by Jeanson and colleagues, NSCLC patients with G12D, G12V, and G13C KRAS mutations exhibited higher PD-L1 expression compared to patients with G12A or G12C KRAS mutations—although the clinical outcomes with immunotherapy were not significantly different between the groups (127). This evidence concerns the gene CD274 and non-small cell lung carcinoma.